Arsenic trioxide as a novel anti-glioma drug: a review

Arsenic trioxide as a novel anti-glioma drug: a review

Arsenic trioxide has proven a robust anti-tumor impact with little toxicity when used within the therapy of acute promyelocytic leukemia (APL). An impact on glioma has additionally been proven. Its mechanisms embody regulation of apoptosis and autophagy; promotion of the intracellular manufacturing of reactive oxygen species, inflicting oxidative harm; and inhibition of tumor stem cells.…

Read More
Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience

Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience

Acute promyelocytic leukemia is a variant of acute myeloid leukemia characterised by t(15;17) and PML/RAR alfa fusion gene. The invention of the molecular pathogenesis has led to entitle all-trans retinoic acid (ATRA) as the primary focused remedy for acute leukemia. It’s often related to anthracycline-based chemotherapy with excessive response charges, however potential long-term sequelae together…

Read More
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia

Molybdenum Trioxide purified Antimony Trioxide extrapurified AR Molybdenum Trioxide extrapurified AR Pyridine-Sulfur Trioxide Complex Lead Titanium Trioxide Sulfur Trioxide Pyridine Complex

Acquired genetic mutations can confer resistance to arsenic trioxide (ATO) within the remedy of acute promyelocytic leukemia (APL). Nonetheless, such resistance-conferring mutations are uncommon and don’t clarify most illness recurrence seen within the clinic. Now we have generated secure ATO-resistant promyelocytic cell strains which are additionally much less delicate to ATRA and the mix of…

Read More